

Anti-CD22 [OX-97] VivopureX 25 mg, 25 mg, Ab00584-2.3-VXX View online

Anti-CD22 [OX-97] VivopureX 25 mg Ab00584-2.3-VXX

This antibody was created using our proprietary Fc Silent[™] engineered Fc domain containing key point mutations that abrogate binding to Fc gamma receptors.

This chimeric mouse antibody was made using the variable domain sequences of the original Rat IgG1 format, for improved compatibility with existing reagents, assays and techniques.

Isotype and Format: Mouse IgG2a, Fc Silent[™], Kappa Clone Number: OX-97 Alternative Name(s) of Target: Lyb-8; BL-CAM; B-cell receptor CD22; B-lymphocyte cell adhesion molecule; Sialic acid-binding Ig-like lectin 2; Siglec-2; T-cell surface antigen Leu-14; OX97; MRC OX 97; UniProt Accession Number of Target Protein: P35329 Published Application(s): WB, FC Published Species Reactivity: Mouse Immunogen: This antibody was prepared by immunizing PVG rats. Specificity: This antibody recognizes domain 2 of murine CD22, which is expressed on the surface of a subpopulation of mature B lymphocytes. Application Notes: Antibody First Published in: PMID:

Note on publication:

Product Form

Size: 25 mg VivopureX products are produced at high purity (>98%), low endotoxin (<0.5 EU/mg) and are formulated without preservatives. These antibodies are chimerized to have an Fc domain matching their target species to reduce immunogenicity and give you the optimal effector function for your experiment. As a result VivopureX products are the ideal choice for in vivo research applications.

Purification: Protein A affinity purified

Supplied In: PBS only.

Storage Recommendation: All VivopureX products are formulated in PBS only without addition of preservatives. To ensure optimal storage and prevent microbial contamination, only open and dispense under sterile conditions.

Concentration:

>=1mg (see vial label for exact conc)

Important note – This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.